IMTX
ImmaticsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
Current thesis
Successful clinical readouts and a partnering deal validate the TCR approach, significantly derisking the pipeline and enabling re-rating toward mid-to-high teens per share; commercialization or buyout optionality could push value higher.
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta -3.8.
What can break
Clinical setbacks, slower-than-expected enrollment, or need for recurrent equity raises create dilution and downward re-rating; manufacturing or regulatory delays could keep shares under pressure.
Momentum
11
Value
41
Sentiment
73
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $12.00 · Bull $18.00 · Bear $6.00
Data freshness
Prices
As of 2026-07-20
Fundamentals
As of 2026-07-21 • Vendor: Data Vendor v1
Scores
As of 2026-07-20 • Model: HYBRID_IC_RP
AI Memo
As of 2025-11-21 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-07-20
Investment thesis
As of 2026-07-20
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $18.22
Why
Momentum11 · Δ7d -1.1
Value41 · Δ7d +0.0
Sentiment73 · Δ7d -3.8
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Sentiment · See AI snapshot
Momentum
11
26% active weight
Current posture
7d trendFlat
Δ7d
-1.1
Δ21d
-3.8
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
-0.1
Sentiment
73
34% active weight
Current posture
7d trendSoftening
Δ7d
-3.8
Δ21d
-2.8
Why this grade
Composite grade D. Momentum 10.7 / Value 41.1 / Sentiment 73.4
Fundamentals (TTM)As of 2026-07-21
Fundamentals (TTM)
As of 2026-07-21
Market Cap
$1.26B
Beta
1.36
Shares Out
134.1M
P/E (TTM) · Derived
-5.2
P/S (TTM)
11.93
P/FCF (TTM) · Derived
-5.28
Rev YoY
-54.5%
EPS YoY
+45.6%
Gross Margin
-
Op Margin
-167.8%
Net Debt
-$532.85M
Current Ratio
8.78
As of 2026-07-20 • Updated nightlySource: Internal modelMethodology